The Next Generation Sequencing for this study was performed by Circulogene. The methodology uses cfDNA to utilize a 50 gene panel which offers the opportunity to identify genetic alterations that can be utilized to direct therapy. In recurrent ovarian cancer patients, the study shows success in providing patients with NGS-directed therapy. Please review this poster presentation for in-depth information regarding background, objectives, methods, results and conclusions from the analysis study.


AACR2017_Final_010317_Circ_

Analysis of Clinical Cancer Gene Panels by Next Generation Sequencing in Tumor and Circulating Cell-Free DNA Samples in Recurrent Ovarian Cancer Patients

Background: Molecular profiling can play an important role in making treatment decisions and will be a critical component in optimizing personalized medicine cancer care. Utilizing personalized medicine in high-volume clinical environments requires interdisciplinary expertise. The lack of an organized infrastructure in performing next generation sequencing (NGS), integrating these results into the electronic medical record (EMR), and guiding clinicians on how to interpret these tests for clinical decision making remains a barrier in the implementation of personalized medicine.

Objectives:

1. To build an infrastructure of molecular profiling through NGS in patients with recurrent ovarian cancer that could impact clinical care in a Personalized Medicine Initiative (PMI).

2. To analyze the results of NGS on tumor and plasma cell free DNA (cfDNA) in patients with recurrent ovarian cancer.

3. To generate evidence of the feasibility of providing genotype-guided therapy to patients with recurrent ovarian cancer.

Methods

Under IRB approval, patients with recurrent ovarian cancer were consented from September 2015 to November 2016.

– NGS was performed on archival tumor and on cfDNA at the time of enrollment.

– Before March 2016, NGS was performed on tumor using a 65 gene panel from Genomic Pathology Service (GPS) at Washington University.

– After March 2016, all NGS was performed using a 315 gene FoundationOne (FO) panel at Foundation Medicine.

– NGS was performed on cfDNA utilizing a 50 gene panel performed at Circulogene Theranostics.

– A Personalized Medicine Letter (PML) summarizing the results of the tumor NGS and recommendations was placed in the patients’ EMR.

– Treatment for patients enrolled in the PMI ovarian project was determined by the patients’ physician.

– NGS results detailing genomic alterations were stored in the Ovarian Personalized Medicine Initiative (OVPMI) database.